High-Level Overview
OpenEvidence is an AI-powered medical copilot designed to help physicians make high-stakes clinical decisions at the point of care. Its mission is to organize and expand the world’s medical knowledge so that every clinician can access the latest, evidence-based insights instantly. The company’s core product is a medical chat platform that allows doctors to ask complex patient care questions and receive immediate, cited answers drawn from over 35 million peer-reviewed medical publications. OpenEvidence serves verified U.S. physicians at no cost, streamlining clinical decision-making by synthesizing vast amounts of medical literature and reducing the risk of AI hallucinations by only responding when evidence exists. The platform is now used by more than 40% of U.S. physicians, with over 8.5 million consultations logged monthly as of mid-2025, and is rapidly expanding its footprint across hospitals and clinics nationwide.
Origin Story
OpenEvidence was founded in 2022 by Daniel Nadler, a Harvard Ph.D. and former founder of Kensho (acquired by S&P Global), alongside Zack Ziegler, a machine learning researcher from Harvard. The idea emerged from the founders’ recognition of the overwhelming volume of medical literature and the growing physician shortage, which together create a critical gap in timely, reliable clinical decision support. Early traction was fueled by rapid physician adoption, word-of-mouth growth, and strategic partnerships with leading medical institutions like the Mayo Clinic, NEJM, and JAMA. By 2023, OpenEvidence’s AI model achieved a 90% score on the USMLE, rising to 100% by 2025, and the company was recognized with Daniel Nadler’s inclusion in the TIME100 Health list.
Core Differentiators
- Evidence-Based AI: Answers are sourced exclusively from peer-reviewed medical literature, with direct citations for every response.
- No-Hallucination Policy: The platform only responds when evidence exists, ensuring reliability and trust.
- Broad Clinical Utility: Beyond Q&A, OpenEvidence supports tasks like drafting letters, performing calculations, and synthesizing complex research.
- Free Access for Clinicians: Physicians can use the platform at no cost, driving rapid adoption and organic growth.
- DeepConsult Feature: Advanced reasoning models synthesize findings across hundreds of studies, delivering comprehensive research reports in minutes.
- Pharma Engagement: Unique access to physicians at the moment of clinical decision-making, enabling contextually relevant information delivery.
Role in the Broader Tech Landscape
OpenEvidence is riding the wave of generative AI and the urgent need for clinical decision support in healthcare. The timing is critical: with medical research doubling every five years and a projected physician shortfall of nearly 100,000 in the U.S. by 2030, the demand for efficient, trustworthy AI tools has never been greater. OpenEvidence’s direct-to-clinician approach bypasses traditional institutional barriers, accelerating adoption and influencing how AI is integrated into frontline care. The company is shaping the future of medical AI by setting a new standard for evidence-based, transparent, and clinician-centric technology.
Quick Take & Future Outlook
OpenEvidence is poised to become the foundational AI layer for clinical decision-making, with potential expansion into global markets, new care settings, and deeper integrations with electronic health records. As AI regulation and trust in healthcare AI evolve, OpenEvidence’s commitment to evidence-based answers and transparency will likely set it apart. The company’s influence will grow as it continues to empower physicians, improve patient outcomes, and redefine the role of AI in medicine. Just as the iPhone transformed personal technology, OpenEvidence is transforming how doctors access and use medical knowledge—making high-stakes decisions faster, safer, and more informed.
